Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00067327 · ClinicalTrials.gov registry record · Phase 2
Treatment of Multiple Sclerosis Using Over the Counter Inosine
A Phase 2 study, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00067327 is a Phase 2 study that has completed, run by National Center for Complementary and Integrative Health (NCCIH). The registered enrollment target is 30 participants.
The verdict
NCT00067327, a Phase 2 study, has completed, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether raising low levels of the natural antioxidant uric acid by the administration of a precursor, inosine, has any therapeutic effect on the progression of Relapsing Remitting Multiple Sclerosis (RRMS) and secondary progressive Multiple Sclerosis (MS).
Interventions
- DRUG Inosine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2002-02 |
| Est. Completion | 2005-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00067327
The ClinicalTrials.gov registry entry for NCT00067327 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Center for Complementary and Integrative Health (NCCIH), which has 203 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Inosine is the first listed.
NCT00067327 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00067327 about?
NCT00067327 is a clinical study titled "Treatment of Multiple Sclerosis Using Over the Counter Inosine". The purpose of this study is to determine whether raising low levels of the natural antioxidant uric acid by the administration of a precursor, inosine, has any therapeutic effect on the progression of Relapsing Remitting Multiple Sclerosis (RRMS) and secondary progressive Multiple Sclerosis (MS).
What is the current status of trial NCT00067327?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2002-02. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00067327?
The interventions under investigation include: Inosine (DRUG).
Who is sponsoring clinical trial NCT00067327?
This trial is sponsored by National Center for Complementary and Integrative Health (NCCIH), which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.